![]() ![]() ![]() The second dose of the Pfizer-BioNTech vaccine was linked to about twice as many cases as the second dose of the vaccine made by Moderna. Most cases have been mild, but 15 patients remain in hospitals. The numbers are higher than would be expected for that age group, officials said, but have not yet been definitively linked to the vaccines.Īs of May 31, 216 people had experienced myocarditis or pericarditis after one dose of either vaccine, and 573 after the second dose. Advisers to the agency will meet on June 18 to explore the potential links to the complications: myocarditis, inflammation of the heart muscle, and pericarditis, inflammation of the membrane surrounding the heart.Ībout two-thirds of the cases were in young males, with a median age of 30 years. Tom Shimabukuro, a vaccine expert at the Centers for Disease Control and Prevention who presented the data. “We clearly have an imbalance there,” said Dr. More than half of the heart problems were reported in people ages 12 to 24, while the same age group accounted for only 9 percent of the millions of doses administered. But the reports have worried some researchers. Not all of the cases are likely to be verified or related to vaccines, and experts believe the benefits of immunization far outweigh the risk of these rare complications. Paul Ratje for The New York Timesįederal officials are reviewing nearly 800 cases of rare heart problems following immunization with the coronavirus vaccines made by Pfizer-BioNTech and Moderna, according to data presented at a vaccine safety meeting on Thursday. As of May 31, 216 people had experienced heart problems after one dose of the Pfizer or Moderna vaccines, and 573 after the second dose. ![]() A nurse prepares a dose of the Pfizer-BioNTech vaccine in Albuquerque at the end of May. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |